Levels of Evidence According to Study Design Grade
Definition I
II-1 II-2 II-3
III Abbreviations Randomized controlled trials
Controlled trials without randomization Cohort or case control analytic studies
Multiple time series Dramatic uncontrolled experiments
Opinion of respected experts Descriptive epidemiology
AFP, alphafetoprotein; BCLC, Barcelona Clinic Liver Cancer; bid, twice a day; CT, computed tomography; HCC, hepatocellular carcinoma; LYG, life years gained; MDCT, multidetector computed tomography scan; MRI, magnetic resonance imaging; NAFLD, nonalcoholic fatty liver disease; PS, performance status; RFA, radiofrequency ablation; TACE, transarterial chemoembolization
Source Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-1022. PMID: 21374666
Disclaimer
This Guideline attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgement concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool.
HCC05122b
5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2012 All rights reserved